Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue
Mandate

Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue

February 10, 2021 Capital Markets and Public M&A

Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore Pharma receives gross proceeds of SEK 336 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. Vicore Pharma intends to use the issue proceeds to finance the phase III clinical trial in COVID-19 patients anticipated to start in Q2 2021 and expected to be fully recruited by the end of Q4 2021, C21 manufacturing and scale up activities including tech transfer, GMP manufacturing and GMP production of capsules, strengthening the company’s IPF franchise and general corporate purposes.

The share issue is subject to subsequent approval at the extraordinary general meeting to be held on 5 March 2021.

Vinge’s team has consisted of Jesper Schönbeck, Rikard Lindahl, Joel Magnusson and Linnea Petersson.

 

Related

Vinge advises Setra Trävaror in conjunction with the sale of Malå Såg to HS Timber

 The Austrian company HS Timber Group has entered into an agreement to acquire 100 per cent of the shares in the Swedish wood processing company Malå Såg AB from Setra Trävaror AB, a subsidiary of Setra Group AB. The transaction remains subject to approval from the relevant public authorities.
October 29, 2025

Vinge has advised Advania on the acquisition of Visuell Teknik

 Advania has acquired Visuell Teknik, a Swedish provider of audiovisual and meeting technology solutions.
October 28, 2025

Vinge has advised Acrinova in connection with voluntary share redemption offering

 Vinge has advised Acrinova AB (publ) in connection with its voluntary share redemption offering. The offer comprised approximately one-third of the shares in Acrinova, and the acceptance rate reached approximately 97.34 percent, representing a redemption value of approximately SEK 367.4 million.
October 27, 2025